CYP1A1 and lung carcinoma: The combination NAT2 slow-CYP1A1 rapid acetylator were at highest risk for lung adenocarcinoma in non-smoking females [36] or the NAT2-CYP1A1 rapid acetylators may also predispose higher risk to lung cancer in female never smokers [22].